Administration of cardiac mesenchymal cells modulates innate immunity in the acute phase of myocardial infarction in mice
Abstract Although cardiac mesenchymal cell (CMC) therapy mitigates post-infarct cardiac dysfunction, the underlying mechanisms remain unidentified. It is acknowledged that donor cells are neither appreciably retained nor meaningfully contribute to tissue regeneration—suggesting a paracrine-mediated...
Enregistré dans:
Auteurs principaux: | Yi Kang, Marjan Nasr, Yiru Guo, Shizuka Uchida, Tyler Weirick, Hong Li, Jae Kim, Joseph B. Moore, Senthilkumar Muthusamy, Roberto Bolli, Marcin Wysoczynski |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e60037ebf1604f059252e71ae039ca99 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Innate Lymphoid Cells and Myocardial Infarction
par: Wenling Yang, et autres
Publié: (2021) -
Cardiac Tissue Engineering for the Treatment of Myocardial Infarction
par: Dongmin Yu, et autres
Publié: (2021) -
Optimization of Timing and Times for Administration of Atorvastatin‐Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction
par: Jun Xu, et autres
Publié: (2019) -
Eosinophils improve cardiac function after myocardial infarction
par: Jing Liu, et autres
Publié: (2020) -
Haematopoietic and cardiac GPR55 synchronize post-myocardial infarction remodelling
par: Sarah-Lena Puhl, et autres
Publié: (2021)